Methods for measuring proteasome activity: Current limitations and future developments

Andrea Liggett; Lisa Crawford; Brian Walker; Treen Morris; Alexandra Irvine

doi:10.1016/j.leukres.2010.07.003

Methods for measuring proteasome activity: Current limitations and future developments

Andrea Liggett, Lisa Crawford, Brian Walker, Treen Morris, Alexandra Irvine

Research output: Contribution to journal › Article › peer-review

36 Citations (Scopus)

Abstract

The proteasome has been validated as a therapeutic target, with proteasome inhibitors showing particular efficacy in the treatment of Multiple Myeloma. A wide range of methods have been developed to profile proteasome activity. These include the current method of choice fluorogenic peptide substrates, as well as bioluminescent imaging, immunological methods, and more recently, site-specific fluorescent probes. The aim of this review is to evaluate the currently available methods for profiling proteasome activity and their suitability for use in translational studies. Ongoing development of techniques for profiling proteasome activity will facilitate future research into proteasome-related pathologies, thus accelerating the development of more specific drug regimes. (C) 2010 Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	1403-1409
Number of pages	7
Journal	Leukemia research
Volume	34
Issue number	11
DOIs	https://doi.org/10.1016/j.leukres.2010.07.003
Publication status	Published - Nov 2010

ASJC Scopus subject areas

Cancer Research
Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2010.07.003

Cite this

@article{be1e5f0cbcdf42d4b330cee3179d0f01,

title = "Methods for measuring proteasome activity: Current limitations and future developments",

abstract = "The proteasome has been validated as a therapeutic target, with proteasome inhibitors showing particular efficacy in the treatment of Multiple Myeloma. A wide range of methods have been developed to profile proteasome activity. These include the current method of choice fluorogenic peptide substrates, as well as bioluminescent imaging, immunological methods, and more recently, site-specific fluorescent probes. The aim of this review is to evaluate the currently available methods for profiling proteasome activity and their suitability for use in translational studies. Ongoing development of techniques for profiling proteasome activity will facilitate future research into proteasome-related pathologies, thus accelerating the development of more specific drug regimes. (C) 2010 Elsevier Ltd. All rights reserved.",

author = "Andrea Liggett and Lisa Crawford and Brian Walker and Treen Morris and Alexandra Irvine",

year = "2010",

month = nov,

doi = "10.1016/j.leukres.2010.07.003",

language = "English",

volume = "34",

pages = "1403--1409",

journal = "Leukemia research",

issn = "1873-5835",

publisher = "Elsevier Ltd",

number = "11",

}

TY - JOUR

T1 - Methods for measuring proteasome activity: Current limitations and future developments

AU - Liggett, Andrea

AU - Crawford, Lisa

AU - Walker, Brian

AU - Morris, Treen

AU - Irvine, Alexandra

PY - 2010/11

Y1 - 2010/11

N2 - The proteasome has been validated as a therapeutic target, with proteasome inhibitors showing particular efficacy in the treatment of Multiple Myeloma. A wide range of methods have been developed to profile proteasome activity. These include the current method of choice fluorogenic peptide substrates, as well as bioluminescent imaging, immunological methods, and more recently, site-specific fluorescent probes. The aim of this review is to evaluate the currently available methods for profiling proteasome activity and their suitability for use in translational studies. Ongoing development of techniques for profiling proteasome activity will facilitate future research into proteasome-related pathologies, thus accelerating the development of more specific drug regimes. (C) 2010 Elsevier Ltd. All rights reserved.

AB - The proteasome has been validated as a therapeutic target, with proteasome inhibitors showing particular efficacy in the treatment of Multiple Myeloma. A wide range of methods have been developed to profile proteasome activity. These include the current method of choice fluorogenic peptide substrates, as well as bioluminescent imaging, immunological methods, and more recently, site-specific fluorescent probes. The aim of this review is to evaluate the currently available methods for profiling proteasome activity and their suitability for use in translational studies. Ongoing development of techniques for profiling proteasome activity will facilitate future research into proteasome-related pathologies, thus accelerating the development of more specific drug regimes. (C) 2010 Elsevier Ltd. All rights reserved.

U2 - 10.1016/j.leukres.2010.07.003

DO - 10.1016/j.leukres.2010.07.003

M3 - Article

SN - 1873-5835

VL - 34

SP - 1403

EP - 1409

JO - Leukemia research

JF - Leukemia research

IS - 11

ER -

Methods for measuring proteasome activity: Current limitations and future developments

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this